Buy price
26.09
Hims & Hers Health Inc (HIMS) Stock Price Today — Live Chart and Analysis
Hims & Hers (NYSE: HIMS) is a healthcare platform that connects patients with licensed doctors and delivers prescription treatments by subscription.
It focuses on areas like hair loss, sexual health, mental health, skincare, and weight management.
The company produces many of its treatments itself, which helps it keep high profit margins (around 80%). Its model is based on convenience and privacy - offering solutions people may feel uncomfortable discussing in person.
By the end of 2025, Hims & Hers had about 2.5 million subscribers across the US and Europe.
Sell price
26.07
Hims & Hers Health Inc chart
Price Performance
1 week
+1.06% +1.06%
+1.06% +1.06%
1 month
-1.7% -1.7%
-1.7% -1.7%
YTD
+3.31% +3.31%
+3.31% +3.31%
Year
+68.24% +68.24%
+68.24% +68.24%
5 years
-33.87% -33.87%
-33.87% -33.87%
Information regarding past performance is not a reliable indicator of future performance.
Hims & Hers Health Inc HIMS Profile
- Sector Health Care
- Industry Health Care Providers & Services
- Country United States
- Founded 2017
- ISIN US4330001060
- CEO Andrew Dudum
HIMS
Hims & Hers reported strong results in 2025. Revenue reached $2.35 billion, up 59%, while adjusted profit (EBITDA) grew 80% to $318 million. Gross margins stayed high at around 80%, and the company reported $128 million in net income - its second year of profitability. Much of this growth came from weight-loss treatments (GLP-1 drugs) sold at lower prices than branded versions. However, in early 2026, the situation changed. The FDA ruled that the company’s oral GLP-1 product was not approved and required it to be removed from the market. The company also disclosed an SEC investigation. Following this, the stock dropped about 40% from its peak. For 2026, the company expects revenue of $2.7–$2.9 billion, but future growth depends on how these regulatory issues are resolved. A key positive development is a partnership with Novo Nordisk to distribute its weight-loss drug Wegovy through the Hims & Hers platform, which boosted the stock. Going forward, the main things to watch are the regulatory outcome for GLP-1 products, how the Novo Nordisk partnership performs, and whether the company can expand into new areas like diagnostics and longevity services.
How can I buy Hims & Hers Health Inc?
- 1
Sign up
Create an account and complete a quick verification.
- 2
Deposit funds
Add money to your wallet via card, bank transfer, or crypto.
- 3
Trade
Choose HIMS, set the amount, and click buy or sell — that’s it!
Hims & Hers Health Inc
HIMS
26.08
Instrument CFD
FAQ